Stereotactic body radiation therapy for primary lung cancers clinically diagnosed without pathological confirmation: a single-institution experience
Stereotactic body radiation therapy for primary lung cancers clinically diagnosed without pathological confirmation: a single-institution experience
复制标题
DOI：
10.1007/s10147-014-0698-y
复制
发表时间：
2015-02-01
影响因子：
3.3
通讯作者：
Honda, Hiroshi
中科院分区：
文献类型：
--
作者：
Yoshitake, Tadamasa;Nakamura, Katsumasa;Honda, Hiroshi
背景对于医学上不能手术的患者，肺部小病变的病理诊断有时很困难。本研究的目的是评价立体定向体部放射治疗（SBRT）治疗临床诊断为原发性肺癌但未经病理证实的肺部病变的不良事件和结局。方法2003年4月至2011年4月，对88例临床诊断为原发性肺癌的肺部小病变患者进行了SBRT治疗。中位肿瘤大小为19 mm（范围8-40 mm）。所有患者的放射剂量为48戈伊，分4次。随访6-91个月，中位随访23个月。局部控制率、无进展生存率和3年总生存率分别为90%、67%和80%。2例患者（2.3%）发生2级放射性肺炎，6例患者（6.8%）发生2级肋骨骨折。有没有3级或更大的不良事件。结论SBRT似乎是一个安全有效的治疗选择，临床诊断为原发性肺癌，病理证实的小肺部病变。
Background Pathological diagnosis of small lung lesions is sometimes difficult in medically inoperable patients. The purpose of this study was to evaluate the adverse events and the outcomes of stereotactic body radiation therapy (SBRT) for lung lesions which were clinically diagnosed as primary lung cancer without pathological confirmation.Methods Between April 2003 and April 2011, 88 patients with small lung lesions which were clinically diagnosed as primary lung cancer were treated with SBRT. The median tumor size was 19 mm (range 8-40 mm). The radiation dose was 48 Gy in four fractions in all patients. The median follow-up was 23 months (range 6-91 months).Results Recurrence was observed in 13 patients. The local control rate, progression-free survival rate, and overall survival rate at 3 years were 90, 67, and 80 %, respectively. Two patients (2.3 %) had Grade 2 radiation pneumonitis, and six patients (6.8 %) had Grade 2 rib fractures. There were no adverse events of Grade 3 or greater.Conclusions SBRT appears to be a safe and effective treatment option for small lung lesions that are clinically diagnosed as primary lung cancer without pathological confirmation.